Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
224
datasets available to search
ShareScore release 0.9.0
Dataset results
224 results for “Antihypertensive”
Antihypertensive drug metabolite screening toy dataset for MS/MS application
<p><strong>Objectives :</strong></p> <p>Detect and visualize antihypertensive drug metabolites in untargeted metabolomics experiments</p> <p><strong>Cohort :</strong></p> <p>6/26 patients on antihypertensive therapy</p> <p><strong>Mass spectrometer :</strong></p> <p>Thermo Q-Exactive coupled to pHILIC chromatography using data dependent analysis (DDA) MS/MS gas-phase experiments</p>
A floating 3D printed formulation for the coadministration and sustained release of antihypertensive drugs - Underlying CT data
<p>Underlying CT data of <strong>"A floating 3D printed formulation for the coadministration and sustained release of antihypertensive drugs"</strong></p> <p>Paola Zgouro1, Orestis L. Katsamenis3,4, Thomas Moschakis5, Georgios K. Eleftheriadis6, Athanasios S. Kyriakidis6, Konstantina Chachlioutaki1,2, Paraskevi Kyriaki Monou1,2, Marianna Ntorkou7, Constantinos K. Zacharis7, Nikolaos Bouropoulos8,9, Dimitrios G. Fatouros1,2, Christina Karavasili1, Christos I. Gioumouxouzis1</p> <p><em>1 Laboratory of Pharmaceutical Technology, Department of Pharmaceutical Sciences, Aristotle University of Thessaloniki, GR-54124, Thessaloniki, Greece</em><br><em>2 Center for Interdisciplinary Research and Innovation (CIRI-AUTH), 57001 Thessaloniki, Greece</em><br><em>3 μ-VIS X-Ray Imaging Centre, Faculty of Engineering and Physical Sciences, University of Southampton, Southampton, SO17 1BJ, UK</em><br><em>4 Institute for Life Sciences, University of Southampton, University Rd, Highfield, Southampton, SO17 1BJ, UK</em><br><em>5 Department of Food Science and Technology, School of Agriculture, Aristotle University of Thessaloniki, GR-541 24 Thessaloniki, Greece</em><br><em>6 Pharmacare Premium Limited, R&D Department, HHF003 Hal Far Industrial Estate, Birzebbugia BBG3000, Malta</em><br><em>7 Laboratory of Pharmaceutical Analysis, Department of Pharmacy, Aristotle University of Thessaloniki, GR-54124, Greece</em><br><em>8 Department of Materials Science, University of Patras, 26504 Rio, Patras, Greece</em><br><em>9 Foundation for Research and Technology Hellas, Institute of Chemical Engineering and High Temperature Chemical Processes, Patras, Greece</em></p> <p><strong>Microfocus Computed Tomography (μCT)</strong></p> <p>X-ray microfocus computed tomography (μCT) was employed for the characterization of the microstructure of the printed object, assessing the overall volume, porosity, local thickness and other printing defects. The imaging took place at the University of Southampton’s μ-VIS X-ray Imaging Centre (<a title="&mu;-VIS X-ray Imaging Centre at the University of Southampton" href="https://www.muvis.org" target="_blank" rel="noopener">www.muvis.org</a>) / 3D X-ray Histology facility using a customized μCT scanner optimized for 3D X-ray histology (<a title="3D X-ray Histology facility at University of Southampton" href="https://www.xrayhistology.org" target="_blank" rel="noopener">www.xrayhistology.org</a>) (<a title="A high-throughput 3D X-ray histology facility for biomedical research and preclinical applications" href="https://doi.org/10.12688/wellcomeopenres.19666.2" target="_blank" rel="noopener">Katsamenis et al., 2023</a>) based on Nikon’s XTH225ST system (Nikon Metrology, Castle Donington, UK). The scanner was operated at 110 kVp / 90 μA (9.9 W), with the X-ray beam prefiltered using 0.04 mm of aluminum. The source-to-object and source-to-detector distances were 28.4 mm and 1136.7 mm, respectively, resulting in a magnification factor of 40x. Acquisition parameters included 2201 projections, averaging 4 frames per projection, with an exposure time of 177 ms per projection. The 2850 x 2850 dexels detector was binned 2x (virtual detector: 1425 × 1425 dexels), resulting in an isotropic voxel edge of 7.5 μm. The reconstructed data underwent visualization and analysis using Dragonfly software (Comet Technologies Canada Inc.; software available at http://www.theobjects.com/dragonfly).</p>
Dataset related to article "ANTIHYPERTENSIVE DRUGS FOR SECONDARY PREVENTION AFTER ISCHEMIC STROKE OR TRANSIENT ISCHEMIC ATTACK"
<p>we performed a systematic review and meta-analysis in order to summarize the current evidence on blood pressure (BP)-lowering drugs for secondary prevention in patients with ischemic stroke or transient ischemic attack. We searched MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials up to January 31, 2020. We included randomized controlled trials comparing any specific BP-lowering drug, as monotherapy or combination, with either a control or another BP-lowering drug. Eight studies that enrolled 33 774 patients with ischemic stroke or transient ischemic attack were included in the meta-analysis. Primary outcomes were all-cause mortality and the proportion of patients who developed a stroke following BP-lowering drug use, irrespective of its nature (ischemic or hemorrhagic) and severity. Secondary outcomes included the proportion of patients who developed an ischemic stroke; an ischemic stroke or TIA irrespective of severity; a hemorrhagic stroke, defined as an acute extravasation of blood into and around the brain parenchyma (subdural hematoma and epidural hematoma were excluded); a cardiovascular event defined as any sudden death, fatal or nonfatal acute coronary syndrome, stroke, intracranial hemorrhage, or pulmonary embolism; a fatal cardiovascular event defined as any death due to any vascular cause, including unexplained sudden death; and serious adverse events of hypotension, syncope, injurious falls, electrolyte abnormalities, bradycardia, or acute renal failure. We recorded the outcomes at the longest available follow-up for all analyses. We considered the following potential sources of heterogeneity (effect modifiers): inclusion limited to hypertensive patients (normotensive and hypertensive patients versus hypertensive patients only) or noncardioembolic ischemic strokes (all ischemic strokes versus noncardioembolic ischemic strokes only), time from the index ischemic event to randomization (acute patients treated within the first week versus stabilized patients treated after the first week), and trial risk of bias.</p>
A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure
ClinicalTrials.gov study NCT00791258. IPD Sharing: YES. Countries: 1. Publications: 2.
An investigation of antihypertensive class, dementia, and cognitive decline
Objective High blood pressure is one of the main modifiable risk factors for dementia. However, there is conflicting evidence regarding the best antihypertensive class for optimising cognition. Our objective was to determine whether any particular class of antihypertensive was associated with a reduced risk of cognitive decline or dementia using comprehensive meta-analysis including reanalysis of original participant data. Methods To identify suitable studies MEDLINE, Embase and PsycINFO® and pre-existing study consortia were searched from inception to December 2017. Authors of prospective longitudinal human studies or trials of antihypertensives were contacted for data-sharing and collaboration. Outcome measures were incident dementia or incident cognitive decline (classified using the reliable change index method). Data were separated into mid and late-life (>65 years) and each antihypertensive class was compared to no treatment and to treatment with other antihypertensives. Meta-analysis was used to synthesize data. Results Over 50,000 participants from 27 studies were included. Among those aged >65 years, with the exception of diuretics, we found no relationship by class with incident cognitive decline or dementia. Diuretic use was suggestive of benefit in some analyses but results were not consistent across follow-up time, comparator group and outcome. Limited data precluded meaningful analyses in those ≤65 years. Conclusions Our findings, drawn from the current evidence base, support clinical freedom in the selection of antihypertensive regimens to achieve blood pressure goals.
Knowledge of Primary Health Care Nurses at Selected Public Institutions Regarding Prescription of Antihypertensive Drugs
<p>Hypertension has been among the most studied topics of the previous century and has been one of the most significant comorbidities contributing to the development of stroke, myocardial infarction, heart failure, and renal failure. In the mist of that, there is limited data on nurses’ knowledge regarding prescription of antihypertensive drugs in Lesotho. The aim of this study was to assess primary health care nurses’ knowledge regarding prescription of antihypertensive drugs. Quantitative descriptive cross-sectional study of primary health care nurses recruited by purposive sampling was conducted. An electronic questionnaire was used to collect data and data were analyzed using descriptive statistics. Most participants were females and had attained diploma in general nursing and midwifery. A proportion of 26% fully knew the steps to be followed for diagnosing hypertension and only 23% felt highly confident to initiate patients on antihypertensive drugs. Moreover, knowledge on mechanism of action of antihypertensive drugs was poor and less than half only knew antihypertensive drug of choice when there is comorbidity. The study identified that nurses have knowledge deficit regarding prescription of antihypertensive drugs. There is a need for interventions to improve nurses’ knowledge so as to curb hypertension burden. </p>
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
ClinicalTrials.gov study NCT01195662. IPD Sharing: Not stated. Countries: 16. Publications: 2.
Pharmacogenomic Evaluation of Antihypertensive Responses
ClinicalTrials.gov study NCT00246519. IPD Sharing: Not stated. Countries: 1. Publications: 30.
China Antihypertensive Trial in Acute Ischemic Stroke
ClinicalTrials.gov study NCT01840072. IPD Sharing: NO. Countries: 1. Publications: 31.
Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension
ClinicalTrials.gov study NCT02722265. IPD Sharing: YES. Countries: 1. Publications: 1.
Behavioral Economics to Improve Antihypertensive Therapy Adherence
ClinicalTrials.gov study NCT04029883. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension
ClinicalTrials.gov study NCT02412761. IPD Sharing: NO. Countries: 1. Publications: 2.
Antihypertensive Treatment of Acute Cerebral Hemorrhage-II
ClinicalTrials.gov study NCT01176565. IPD Sharing: YES. Countries: 7. Publications: 32.
Pharmacogenomic Evaluation of Antihypertensive Responses 2
ClinicalTrials.gov study NCT01203852. IPD Sharing: Not stated. Countries: 1. Publications: 7.
Antihypertensive Deprescribing in Long-term Care
ClinicalTrials.gov study NCT05047731. IPD Sharing: YES. Countries: 1. Publications: 1.
The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial
ClinicalTrials.gov study NCT00605072. IPD Sharing: Not stated. Countries: 1. Publications: 4.
BedMed-Frail: Does the Potential Benefit of Bedtime Antihypertensive Prescribing Extend to Frail Populations?
ClinicalTrials.gov study NCT04054648. IPD Sharing: YES. Countries: 1. Publications: 2.
Post-Authorization Long-term Safety Surveillance on Antihypertensive Treatment With Kanarb® (Fimasartan)
ClinicalTrials.gov study NCT02385721. IPD Sharing: Not stated. Countries: 1. Publications: 1.
The Effect of Antihypertensive Drugs on Severity of Anaphylaxis and Side-effects During Venom Immunotherapy
ClinicalTrials.gov study NCT04269629. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Addressing Antihypertensive Medication Adherence Through EHR-enabled Teamlets in Primary Care
ClinicalTrials.gov study NCT05349422. IPD Sharing: YES. Countries: 1. Publications: 4.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.